Financial PerformanceEvolus reported global net revenue of $68.5M in 1Q25, a 15.5% increase from 1Q24, driven primarily by higher volumes and market share gains.
Market PerformanceJeuveau significantly outperformed the overall toxin market and the leading toxin Botox to further grow its market share.
Product LaunchEvolus is expected to benefit from the launch of Evolysse, which the company anticipates will contribute 8-10% of sales.